Rohn Rigby, MD
Family Medicine · Layton, UTNPI 1437283553
Payments from drug & device makers
What this record shows
Novo Nordisk accounts for 60.6% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $2,333, 3.8 times the $613 reported in 2019.
Across 210 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$402
- AstraZeneca$387
- Corcept Therapeutics$296
- AbbVie$214
- Abbott$155
- plus $633 from 25 others
What the payments were for
- Consulting fees$2,13040%
- Food & beverage$3,16060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $3,204 |
| Lilly USA, LLC | 29 | $402 |
| AstraZeneca | 17 | $387 |
| Corcept Therapeutics | 14 | $296 |
| AbbVie | 12 | $214 |
| Abbott | 7 | $155 |
| Amarin Pharma, Inc. | 6 | $104 |
| Kvk-tech, Inc. | 1 | $49 |
| Dexcom, Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $44 |
| Johnson & Johnson(2 entities) | 3 | $41 |
| Acella Pharmaceuticals, LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $32 |
| Strongbridge US Inc. | 1 | $31 |
| GSK | 2 | $25 |
| Novartis | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Exeltis, USA Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Merck | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Pfizer | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Bolton Medical Inc | 1 | $12 |
| Amgen | 1 | $12 |
| Optinose US, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $9 |
| Clarus Therapeutics Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$118
How this compares
$5,290 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $208,785 |
| MounjaroTirzepatide | 114 | $122,892 |
| FarxigaDapagliflozin Propanediol | 132 | $103,906 |
| TrulicityDulaglutide | 27 | $33,795 |
| JardianceEmpagliflozin | 34 | $20,576 |
| Liothyronine Sodium | 179 | $5,451 |
| ProgesteroneProgesterone, Micronized | 118 | $5,166 |
| Metformin Hcl ErMetformin Hcl | 264 | $3,616 |
| KlonopinClonazepam | 13 | $3,102 |
| Testosterone Cypionate | 50 | $3,034 |
| Estradiol (Once Weekly)Estradiol | 49 | $2,543 |
| Levothyroxine Sodium | 210 | $1,930 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $1,928 |
| Bupropion XlBupropion Hcl | 27 | $1,308 |
| Naltrexone Hcl | 35 | $995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,204 | $208,785173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $402 | $156,686141 claims |
| AstraZenecaFarxiga | $387 | $103,906132 claims |
| Boehringer IngelheimJardiance | $32 | $20,57634 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $38 | $93414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Layton
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Layne BarkerLayton$13K
- Johnnie CookLayton$9K
- Kevin GardnerLayton$9K
- Jared MorrisLayton$8K
- Jeffery DegrauwLayton$8K
- Rachel HobbsLayton$8K
- Marc AndersonLayton$8K
- Michael SchaellingLayton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.